Zobrazeno 1 - 10
of 404
pro vyhledávání: '"Koenig, Franz"'
A simple device for balancing for a continuous covariate in clinical trials is to stratify by whether the covariate is above or below some target value, typically the predicted median. This raises an issue as to which model should be used for modelli
Externí odkaz:
http://arxiv.org/abs/2408.06760
Autor:
Roig, Marta Bofill, Krotka, Pavla, Hees, Katharina, Koenig, Franz, Magirr, Dominic, Jacko, Peter, Parke, Tom, Posch, Martin
Shared controls in platform trials comprise concurrent and non-concurrent controls. For a given experimental arm, non-concurrent controls refer to data from patients allocated to the control arm before the arm enters the trial. The use of non-concurr
Externí odkaz:
http://arxiv.org/abs/2407.13546
Autor:
Klinglmueller, Florian, Benda, Norbert, Friede, Tim, Fellinger, Tobias, Heinzl, Harald, Hooker, Andrew, Koenig, Franz, Mathes, Tim, Posch, Martin, Stampfer, Florian, Urach, Susanne
While well-established methods for time-to-event data are available when the proportional hazards assumption holds, there is no consensus on the best approach under non-proportional hazards. A wide range of parametric and non-parametric methods for t
Externí odkaz:
http://arxiv.org/abs/2406.12492
Autor:
Brugger, Jonas, Friede, Tim, Klinglmüller, Florian, Posch, Martin, Ristl, Robin, König, Franz
The log-rank test and the Cox proportional hazards model are commonly used to compare time-to-event data in clinical trials, as they are most powerful under proportional hazards. But there is a loss of power if this assumption is violated, which is t
Externí odkaz:
http://arxiv.org/abs/2402.08336
Autor:
Yousefi, Elham, Gewily, Mohamed, König, Franz, Höglinger, Günter, Hopfner, Franziska, Karlsson, Mats O., Ristl, Robin, Zehetmayer, Sonja, Posch, Martin
Measuring disease progression in clinical trials for testing novel treatments for multifaceted diseases as Progressive Supranuclear Palsy (PSP), remains challenging. In this study we assess a range of statistical approaches to compare outcomes measur
Externí odkaz:
http://arxiv.org/abs/2312.08169
Autor:
Klinglmüller, Florian, Fellinger, Tobias, König, Franz, Friede, Tim, Hooker, Andrew C., Heinzl, Harald, Mittlböck, Martina, Brugger, Jonas, Bardo, Maximilian, Huber, Cynthia, Benda, Norbert, Posch, Martin, Ristl, Robin
While well-established methods for time-to-event data are available when the proportional hazards assumption holds, there is no consensus on the best inferential approach under non-proportional hazards (NPH). However, a wide range of parametric and n
Externí odkaz:
http://arxiv.org/abs/2310.05622
Autor:
Freitag, Michaela Maria, Zocholl, Dario, Meyer, Elias Laurin, Gold, Stefan M., Roig, Marta Bofill, De Smedt, Heidi, Posch, Martin, König, Franz
Major Depressive Disorder (MDD) is one of the most common causes of disability worldwide. Unfortunately, about one-third of patients do not benefit sufficiently from available treatments and not many new drugs have been developed in this area in rece
Externí odkaz:
http://arxiv.org/abs/2310.02080
Survival time is the primary endpoint of many randomized controlled trials, and a treatment effect is typically quantified by the hazard ratio under the assumption of proportional hazards. Awareness is increasing that in many settings this assumption
Externí odkaz:
http://arxiv.org/abs/2310.01990
Autor:
Bardo, Maximilian, Huber, Cynthia, Benda, Norbert, Brugger, Jonas, Fellinger, Tobias, Galaune, Vaidotas, Heinz, Judith, Heinzl, Harald, Hooker, Andrew C., Klinglmüller, Florian, König, Franz, Mathes, Tim, Mittlböck, Martina, Posch, Martin, Ristl, Robin, Friede, Tim
For the analysis of time-to-event data, frequently used methods such as the log-rank test or the Cox proportional hazards model are based on the proportional hazards assumption, which is often debatable. Although a wide range of parametric and non-pa
Externí odkaz:
http://arxiv.org/abs/2306.16858
Autor:
Roig, Marta Bofill, Burgwinkel, Cora, Garczarek, Ursula, Koenig, Franz, Posch, Martin, Nguyen, Quynh, Hees, Katharina
Publikováno v:
Trials 2023
Platform trials gained popularity during the last few years as they increase flexibility compared to multi-arm trials by allowing new experimental arms entering when the trial already started. Using a shared control group in platform trials increases
Externí odkaz:
http://arxiv.org/abs/2211.09547